Justin Zelin
Stock Analyst at BTIG
(1.47)
# 3,265
Out of 4,735 analysts
37
Total ratings
23.53%
Success rate
-0.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $3.22 | +86.34% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $22.00 | +90.91% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.46 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $23.15 | +167.82% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $5.70 | +1,478.95% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $2.37 | +406.33% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.19 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $32.87 | +280.29% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $5.39 | +400.93% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $20 → $16 | $4.33 | +269.52% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $30.00 | +203.33% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.94 | +965.08% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.79 | +793.85% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $6.58 | +462.31% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $13.67 | +156.04% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $34.67 | +159.59% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $7.39 | +319.49% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $81.03 | -80.87% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.83 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $2.63 | +280.23% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $3.22
Upside: +86.34%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $22.00
Upside: +90.91%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.46
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $23.15
Upside: +167.82%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $5.70
Upside: +1,478.95%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $2.37
Upside: +406.33%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.19
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $32.87
Upside: +280.29%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $5.39
Upside: +400.93%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $20 → $16
Current: $4.33
Upside: +269.52%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $30.00
Upside: +203.33%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.94
Upside: +965.08%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.79
Upside: +793.85%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $6.58
Upside: +462.31%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $13.67
Upside: +156.04%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $34.67
Upside: +159.59%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $7.39
Upside: +319.49%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $81.03
Upside: -80.87%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.83
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $2.63
Upside: +280.23%